---
document_datetime: 2025-11-24 12:46:18
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spikevax-previously-covid-19-vaccine-moderna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: spikevax-previously-covid-19-vaccine-moderna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.2296427
conversion_datetime: 2025-12-30 22:38:05.830468
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Spikevax

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1 Change in the shelf-life or storage | 24/11/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000303827                     | conditions of the finished product - B.II.f.1.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     | Labelling and PL   |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|-------------------|
| Variation type IB /                   | B.II.c.3 Change in source of an excipient or reagent with TSE risk - B.II.c.3.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/11/2025 | N/A |                    | EMA/VR/0000304729 |
| Variation type IB / EMA/VR/0000303014 | B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/11/2025 | N/A |                    |                   |
| Variation type II / EMA/VR/0000282182 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of final report from study mRNA- 1273-P910 listed as category 3 study in the RMP. This is a multi-database observational study that utilized routinely collected secondary data in the European region to investigate the natural course of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2 in terms of morbidity and identified relevant prognostic factors. | 02/10/2025 |     |                    |                   |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000291533   | B.I.a.6 Changes to the active substance of a vaccine against human coronavirus - B.I.a.6.a Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine - Accepted                                                                                                                                                                                                                                                                                                                                                          | 18/09/2025   | 24/09/2025   | SmPC, Labelling and PL   |                   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------|
| Variation type IB /                     | This was an application for a group of variations. B.II.c.4 Change in synthesis or recovery of a nonpharmacopoeial excipient (when described in the dossier) or a novel excipient - B.II.c.4.z Other changes - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.II.c) Control of excipients - B.II.c.z Other variation - Accepted B.II.c) Control of excipients - B.II.c.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, | 18/09/2025   | N/A          |                          | EMA/VR/0000292694 |

<div style=\"page-break-after: always\"></div>

|                                       | batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type II / EMA/VR/0000272245 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2 and 5.1 of the SmPC in order to update information regarding the data in the paediatric population, based on results from the final report for study mRNA- 1273-P206. This is a Phase 2, two-part study (open-label [part 1] followed by observer- blind/randomised [part 2]) to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 SARS-CoV- 2 Vaccine (Spikevax bivalent Original/Omicron BA.1) in Participants Aged 12 Weeks to <6 Months. | 24/07/2025 | 25/07/2025 | SmPC                   |
| Variation type II / EMA/VR/0000278795 | B.I.a.6 Changes to the active substance of a vaccine against human coronavirus - B.I.a.6.a Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/07/2025 | 25/07/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | coronavirus vaccine - Accepted                                                                                                                                                                                                                                                                                                                                                       |            |            |                 |                   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------|
| Variation type II /                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study mRNA-1273-P901 listed as a category 3 study in the RMP. This is an observational, real-world study of the effectiveness of Spikevax.  | 03/07/2025 | N/A        |                 | EMA/VR/0000266225 |
| Variation type IB / EMA/VR/0000264400 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                        | 30/04/2025 | N/A        |                 |                   |
| Variation type IA / EMA/VR/0000264865 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted | 16/04/2025 | 25/07/2025 | Annex II and PL |                   |

<div style=\"page-break-after: always\"></div>

|                                       | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                           |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000256116 | B.II.c) Control of excipients - B.II.c.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 09/04/2025 | N/A |
| Variation type II / EMA/VR/0000245103 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study mRNA-1273-P203 listed as a category 3 study in the RMP. This is a phase 2/3, randomized, observer-blind, placebo- controlled study to evaluate the safety, reactogenicity, and effectiveness of mRNA- 1273 SARS-CoV-2 vaccine in healthy adolescents 12 to <18 Years of Age. | 27/03/2025 | N/A |
| Variation type IB / EMA/VR/0000253535 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                  | 18/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                     | of the active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB / | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.z Other changes - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.z Other changes - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.z Other | 25/02/2025 | N/A | EMA/VR/0000244889 |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000257883   | - -   | Maintenance   |
|------------------------------|-------|---------------|